Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia.
Saitis
Mixalis
M
Papazisis
Georgios
G
Katsigiannopoulos
Konstantinos
K
Kouvelas
Dimitrios
D
D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000068180:Aripiprazole; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced* / Q000188:drug therapy*; D008134:Long-Term Care; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use*; D015363:Quinolones / Q000627:therapeutic use*; D012563:Schizophrenia, Paranoid / Q000188:drug therapy*; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use*; D055815:Young Adult
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D013844:Thiazoles; C092292:ziprasidone; D013469:Sulpiride; D000077582:Amisulpride; D000068180:Aripiprazole